ClinicalTrials.gg
RecruitingNCT07560085COURAGEUpdated Sep 2, 2026

Catheter-Oriented Unloading and Recovery With a Left Ventricular Assist Gear: Efficacy in Post Cardiotomy Cardiogenic Shock

An interventional study of SynFlow Duro in Cardiogenic Shock, sponsored by ForQaly Medical (Shanghai) Co., Ltd. Recruiting at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by ForQaly Medical (Shanghai) Co., Ltd · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Shock, Cardiogenic with a site in China — 18 open to participants now, 18 under way, none of them phase 3. Shock, Cardiogenic · China.

Planned enrollment
9th of 14
60 · median 82
Started
2026
with 3 others
No phase
12 of 20
11 open now
Primary completion
2027-06
later than 13 of 17 live
Registered
19th of 20
by date
Lead sponsor
1 of 20
ForQaly Medical (Shanghai) Co., Ltd

Among the 20 studies in Shock, Cardiogenic with a site in China, this one is the 9th largest by planned enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2026, is one of 12 with no phase, reaches primary completion later than 13 of the 17 other live ones, and was the 19th registered.

Shock, Cardiogenic

297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

Browse Shock, Cardiogenic studies →

Open to participants now

18 of the 20 studies in Shock, Cardiogenic with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Shock, Cardiogenic with a site in China, or all of them as a file.
02

Study summary

This study is a prospective, multicenter, single-arm clinical trial conducted in China to evaluate the efficacy and safety of a novel left ventricular assist device, SynFlow Duro system, manufactured by ForQaly Medical in the treatment of post cardiotomy cardiogenic shock.

Read the detailed description

This study is a prospective, single-arm clinical trial to be conducted in at least 2 centers in China to evaluate the efficacy an safety of a novel micro-axial flow pump for left ventricular assistance in post cardiotomy cardiogenic shock. The trial population includes those who fail to wean from cardiopulmonary bypass OR have refractory cardiogenic shock after cardiac surgery. Patients with right heart failure will be excluded. Eligible subjects will receive SynFlow system for bridging to cardiac recovery or durable cardiac therapy (cardiac transplantation or implantation of approved Ventricular Assist Device). The primary endpoint is device support success, defined as survival to 30 days post-explant or hospital discharge (whichever is longer) OR to explantation in case of bridging to durable cardiac therapies.

03

Conditions studied

  • Cardiogenic Shock

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18≤Age≤80, any sex.
  • Failure to wean from CPB or cardiogenic shock after cardiac surgery.

Failure to wean from CPB is defined as failed to discontinue CPB or post-weaning CI \<2.2L/min/m2 + PCWP >15mmHg, despite optimal pre-weaning management and receiving at least one high dose inotrope.

Refractory cardiogenic shock is defined as a condition that occurs despite adequate fluid status and meets all the following criteria:

① CI\<2.2L/min/m2 + PCWP>15mmHg despite receiving at least one high dose inotrope or IABP; OR SBP \<80mmHg or MAP\<50mmHg despite receiving at least one high dose intrope + high dose norepinephrine or IABP.

② Presence of at least one signs indicating hypoperfusion: decreased mentation; cold, clammy, ashen or cyanotic extremities or skin or livedo reticularis; urine output\<30ml/h or 0.5ml/kg/h; or lactate>2mmol/L or metabolic acidosis.

- Patient has signed the form.

Exclusion criteria

Exclusion Criteria:

  • Body surface area>2.5m2.
  • Presence of any cardiac assist device (other than an IABP).
  • Right ventricular failure.
  • Evidence of any vascular disease or anatomy precluding placement or deployment of the device (e.g. severely calcified vessel).
  • Evidence of ventricular thrombus.
  • Moderate or severe aortic valve insufficiency/stenosis, or severe aortic valve calcification.
  • Presence of mechanical aortic valve or cardiac contractile device.
  • Obstructive, hypertrophic cardiomyopathy.
  • Presence of uncorrected ventricular septal defect, atrial septal defect or patent foramen ovale.
  • Mechanical manifestation of AMI (e.g. ventricular septal rupture, papillary muscle rupture, ventricular rupture).
  • Any hematological disorder causing fragility of blood vessel or hemolysis.
  • Known allergy or intolerant to heparin.
  • Presence or suspicion of active systemic infection.
  • Cardiopulmonary resuscitative maneuver lasting longer than 20 minutes before device placement.
  • Sustained or non-sustained ventricular tachycardia or ventricular fibrillation unresponsive to medical therapy.
  • Severe hepatic dysfunction, renal failure or severe respiratory failure
  • Pregnant or lactating female.
  • Concomitant enrollment in another drug or device study where the primary endpoint has not yet been completed or that will clinically interfere with the endpoint of this investigation.
  • Other conditions considered unsuitable for participating in this investigation by the investigators.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    SynFlow Duro

    Device: SynFlow Duro

Interventions

  • DeviceSynFlow Duro

    a novel micro-axial flow pump for temporary left ventricular assistance

06

What researchers measure

Primary outcomes

  1. Device support success

    Cardiac recovery (survival to 30 days post-explant or hospital discharge \[which is longer\] without other mechanical support including IABP) or briging to other durable cardiac therapies (heart transplantation or implantation of approved durable ventricular assist device)

    Time frame: Up to 30 days post-explant or hospital discharge (whichever is longer)

Secondary outcomes

  1. Technical success rate

    Technical success is defined as successful device placement, deployment, startup and explantation without any device malfunction

    Time frame: Through device explantation, up to 14 days

  2. Cardiac index change versus baseline

    Time frame: Within 24 hours after device startup

  3. Cardiac output change versus baseline

    Time frame: Within 24 hours after device startup

  4. Pulmonary artery pressure change versus baseline

    Time frame: Within 24 hours after device startup

  5. Mean arterial pressure change versus baseline

    Time frame: Within 24 hours after device startup

  6. Central venous pressure change versus baseline

    Time frame: Within 24 hours after device startup

  7. Device support duration

    Time from device startup to device explanation

    Time frame: Through device explantation, up to 14 days

  8. Time to recovery

    Recovery is defined as survival to 30 days post-explant or hospital discharge (which is longer) without other mechanical support including IABP

    Time frame: From device placement to 30 days post-explant or hospital discharge (whichever is longer)

  9. Major adverse event

    Defined as stroke or death

    Time frame: From device placement to 30 days post-explant or hospital discharge or bridging to other durable cardiac therapies

  10. Minor adverse event

    Defined as minor or major bleeding, hemolysis, limb ischemia, requiring continuous renal placement therapy, ventricular tachycardia or fibrillation requiring cardioversion, sepsis, mechanical complications and major access vascular complications.

    Time frame: From device placement to 30 days post-explant or hospital discharge or bridging to other durable cardiac therapies

  11. Adverse event

    Defined as untoward medical event occurring during the course of clinical investigation, whether or not related to the medical device.

    Time frame: From device placement to 30 days post-explant or hospital discharge or bridging to other durable cardiac therapies

  12. Serious adverse event

    Defined as the event occurring during the course of clinical investigation, which leads to death or serious deterioration in the health, including a life-threatening illness or injury; a permanent impairment of a body structure or a body function; in-patient or prolonged hospitalization; medical or surgical intervention to prevent permanent impairment to a body structure or a body function; foetal distress, foetal death, congenital abnormality or birth defect, etc.

    Time frame: From device placement to 30 days post-explant or hospital discharge or bridging to other durable cardiac therapies

  13. Device deficiency

    Defined as the unreasonable risk that may endanger human health and life safety in the normal use of medical devices during clinical investigations, such as labeling errors, quality problems, malfunctions, etc.

    Time frame: Through device explantation, up to 14 days

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jun 2027, 11 months after the start.

Of 52 interventional studies with no phase under Shock, Cardiogenic, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2026
First posted
Apr 30, 2026
StartActual
Jul 14, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07560085
Lead sponsor
ForQaly Medical (Shanghai) Co., Ltd
Responsible party
Sponsor
First posted
Apr 30, 2026
Start date
Jul 14, 2026
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Sep 2, 2026

Study contacts

Chen Jiang
Contact
cjiang@forqaly.com
+86 13918357410
Liangwan Chen
study chair · Fujian Medical University Union Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion